Previous 10 | Next 10 |
home / stock / nvsef / nvsef news
2023-04-23 12:00:00 ET Biotech deal-making is on a roll, with more than $12B worth of transactions announced over the past week alone, and, according to industry observers, the trend is expected to continue in 2023, supported by macro and certain industry-specific factors. Days after Me...
2023-04-21 13:45:05 ET Summary Shares of CRISPR-Cas9 genomic editor Intellia Therapeutics, Inc. have retreated over 80% since hitting an all-time intraday high of $202.73 in late June 2021. Despite the pullback, very early returns suggest a functional cure for HAE and (possibly) A...
2023-04-19 06:39:26 ET Summary Biotechnology is the second worst performer in healthcare, significantly lagging behind the US market year-to-date. However, there could now be opportunities to get a bargain in the biotechs. Kura Oncology may be of interest to investors as this US b...
2023-04-14 11:28:52 ET Summary Pharmaceuticals/biotechnology is the only subsector with good value and quality scores. Healthcare equipment is the most overvalued one. IXJ: A global alternative to XLV. 10 stocks cheaper than their peers in April. This monthly art...
2023-04-11 10:41:37 ET TG Therapeutics ( NASDAQ: TGTX ) shares rallied for the second straight session on Tuesday to reach a new 52-week high after B. Riley Securities cited a rising trend in demand for the company’s newly approved multiple sclerosis therapy Briumvi. In D...
2023-03-30 09:03:39 ET Cancer-focused biotech Erasca ( NASDAQ: ERAS ) extended gains in the pre-market Thursday after Mizhuho Securities initiated its coverage with a Buy rating and a $9 per share target, citing its upcoming data readouts and liquidity position. “We l...
2023-03-29 15:05:26 ET Summary This portfolio uses historical performance and qualitative business traits to determine low-risk assets. These assets are leading their class and represent sectors that offer lower volatility. Backtesting proves that the constituents outperform t...
2023-03-27 05:45:26 ET The shares of Dutch biotech Pharming Group N.V. ( NASDAQ: PHAR ) added ~24% on Monday in the Amsterdam stock exchange on the announcement of U.S. approval for the rare immune disorder therapy Joenja co-developed with Novartis ( NVS ). The FDA...
2023-03-24 17:46:35 ET Summary Dimensional International Value ETF is an actively managed fund investing in value stocks outside the U.S. Almost 30% of DFIV assets are in financials. Otherwise, it is well-diversified across countries and holdings. DFIV is slightly better t...
2023-03-23 14:00:00 ET Summary In today’s article, I will present 10 dividend growth companies that I currently consider to be particularly attractive. The 10 selected picks have shown an Average Dividend Growth Rate of 12.92% over the past 5 years. At the same time, th...
News, Short Squeeze, Breakout and More Instantly...
Novartis Ag Basel Akt Company Name:
NVSEF Stock Symbol:
OTCMKTS Market:
Novartis Ag Basel Akt Website:
FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond New 70,000-square foot RLT facility is the company’s largest and most advanced in the world to date and centrall...
APPLY-PNH extension data show that continuous Fabhalta ® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved patient-reported fatigu...
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali ® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS) 1,2 iDFS...